Burns James William 4

What Happened
James William Burns, Chief Legal Officer of Agios Pharmaceuticals (AGIO), had 3,000 performance stock units (PSUs) converted and simultaneously received 3,000 restricted stock units (RSUs) on June 18, 2026. The reported transactions show an exercise/conversion (M) of 3,000 derivative units disposed at $0.00 and an award/acquisition (A) of 3,000 derivative units acquired at $0.00. No cash was exchanged and no shares were reported as sold — this is a milestone-triggered award conversion rather than a market purchase or sale.

Key Details

• Transaction date: 2026-06-18; filing date: 2026-06-23 (filed after the transaction; appears to be later than the SEC’s two-business-day Form 4 deadline).
• Transaction types/prices: M (exercise/conversion) 3,000 @ $0.00 (disposed); A (award/acquisition) 3,000 @ $0.00 (acquired).
• Economic value reported on the Form 4: $0.00 for these entries (no immediate cash value realized).
• Shares owned after transaction: not disclosed in the provided filing.
• Footnotes summary:
  • Each PSU is a contingent right to one common share (F1).
  • The PSUs were granted 3/1/2025 and vest based on three specified clinical/research milestones; the specified research milestone was certified met on 6/18/2026. Shares related to this milestone will vest on 12/31/2027, subject to continued service (F2).
  • Each RSU represents a contingent right to one common share (F3).

Context: This action reflects a milestone achievement under the executive’s prior PSU grant and converts contingent performance units into RSUs that still vest in the future (12/31/2027) if the recipient remains employed. It does not represent an open-market purchase or sale and does not provide immediate liquidity or indicate a change in holdings until/if the RSUs ultimately vest and are settled.